Cancer and its Causes in Korea
|
|
- Meghan Bruce
- 5 years ago
- Views:
Transcription
1 Cancer and its Causes in Korea Prof. Dr. David Khayat, MD, PhD Former Head of Medical Oncology at Pitié-Salpêtrière in Paris Former President of the National Cancer Institute in France Harm Reduction Consultant to PMI
2 Agenda Burden of Non-Communicable Diseases Causes of cancer in Korea Cancer development - a matter of dose and response How does cigarette smoke cause cancer Smoking Prevalence Globally and in Korea Or why better, less harmful alternatives are needed 2
3 The Burden of Non-Communicable Diseases 3
4 The Burden of Non-Communicable Diseases (NCDs) Global Burden of NCDs NCDs such as Cardiovascular, Respiratory Disease and Cancer cause: > 39 Mio Death globally in 2016 ~ 9 Mio cancer deaths in 2016 NCD Burden in Korea NCDs such as Cardiovascular, Respiratory Disease and Cancer cause: > 284k death in 2016 > 100k cancer deaths in 2016 Numbers are based on public statistics for Korea Source: Institute for Health Metrics and Evaluation (IHME). GBD Compare Data Visualization. Seattle, WA: IHME, University of Washington, Available from vizhub.healthdata.org/gbd-compare. (Accessed August 8 th 2018) 4
5 Causes of Cancer in Korea 5
6 Risk Factors for Cancer in Korea Korea, All Ages, Both Sexes, Deaths per 100, rank 2016 rank 1 Smoking 1 Smoking 2 Alcohol Use 2 Alcohol Use 3 High Body Mass Index 3 High Fasting Plasma Glucose 4 Diet High in Sodium 4 High Body Mass Index 5 Diet Low in Fruits 6 Unsafe Sex 7 High Fasting Plasma Glucose 5 Ambient Particulate Matter Pollution 6 Diet High in Sodium 7 Diet Low in Fruits 8 Ambient Particulate Matter Pollution 8 Diet Low in Milk Numbers are based on public statistics for Korea Rank Diet High in Red Meat Rank Diet High in Red Meat Rank Source: Institute for Health Metrics and Evaluation (IHME). GBD Compare Data Visualization. Seattle, WA: IHME, University of Washington, Available from vizhub.healthdata.org/gbd-compare. (Accessed August 8 th 2018) 6
7 Cancer development - a matter of dose response 7
8 Events in Carcinogenesis Carcinogenesis Initiation Phase (1 ~ 2 days) Carcinogenesis Promotion Phase (10 ~ 20 years) Carcinogenesis Progression Phase (> 1 year) Genetic damage Tumor Promoting Environment Modified cells (Hyperplasia) appear Adenomas appear Carcinomas appear 8
9 Dose Response What is there that is not poison? All things are poison and nothing is without poison. Solely the dose determines that a thing is not a poison. Paracelsus 9
10 Exposure Outside the body Dose Response Dose Inside the body Response Change in structure or function Source Host Adverse Health Effect Air, Food, Consumables Humans Disease 10
11 RESPONSE Types of Dose Response 100% Non-Carcinogens Carcinogens 0% Low Dose Exposure DOSE The schematic presented here illustrates that the lower the dose, the more reduced is the response and therefore the risk associated with the response Adapted from: Principles of Exposure, Dose, and Response; The Johns Hopkins University,
12 Food: Colorectal Cancer Risk (CRC) CRC Risk through intake of red and processed meat CRC risk through intake of Fish Points in the figure represent median intakes in each category of consumption. Curves generated from calibrated data (solid line) and uncalibrated data ( hatched line ) and upper and lower confidence intervals for calibrated data ( dotted lines ) are shown. Source: Norat, T; Meat, Fish, and Colorectal Cancer Risk: The European Prospective Investigation into Cancer and Nutrition DOI: /jnci/dji164 Journal of the National Cancer Institute, Vol. 97, No. 12, 12
13 Food: Colorectal Cancer Risk (CRC) Red meat is classified as probably carcinogenic and processed meats as carcinogenic to humans. 1 WCRF/AICR recommendation: Limit red meat consumption to 43 g/day, for cancer prevention. 2 So Young Kim however showed that an intake of 43 g / day of red meat 4 lead to an increase in cancer risk in Korea Average consumption in Korea: ~ g/day of red meat. 3 1 International Agency for Research on Cancer (IARC); Bouvard, V.; Loomis, D.; Guyton, K.Z.; Grosse, Y.; Ghissassi, F.E.; Benbrahim-Tallaa, L.; Guha, N.; Mattock, H.; Straif, K. Carcinogenicity of consumption of red and processed meat. Lancet Oncol. 2015, 16, World Cancer Research Fund and American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective; American Institute for Cancer Research (AICR): Arlington, VA, USA, Korea National Health and Nutrition Examination Survey (KNHANES). Available online: 4 Kim, SY; The Role of Red Meat and Flavonoid Consumption on Cancer Prevention: The Korean Cancer Screening Examination Cohort; Nutrients 2017, 9, 938; doi: /nu
14 Odd Ratio Smoking: Lung Cancer Years of Cigarette Smoking Cigarette Smoking and Lung Cancer: Modeling Total Exposure and Intensity; Jay H. Lubin and Neil E. Caporaso; Cancer Epidemiol Biomarkers Prev March (15) (3) ; DOI: / EPI
15 How does cigarette smoke cause cancer? 15
16 Carcinogens in Cigarette Smoke Tobacco smoke contains more than 6000 chemicals as well as solid ultrafine particles of them have been listed by the FDA as Harmful and Potentially Harmful Constituents (HPHCs). 2 The majority are classified as carcinogens or potential carcinogens. 2 1 Rodgman A, Perfetti TA. The chemical components of tobacco and tobacco smoke 2nd ed: CRC Press, Taylor & Francis Inc (United States); Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act; 16
17 Understanding Cancer Potency of Carcinogens* Carcinogens Compound IARC Class Tobacco Smoke (n=309) Mean Concentration (μg/ml) Heat-Not-Burn (n=44) E-Cigarettes (n=44) Nicotine Inhaler (n=1) % Reduction* % Reduction* % Reduction* Acrylonitrile 2B % NR 99.8% 1,3 - Butadiene % NR 99.9% BDL: Below detection limit; NR: Not reported * compared to Tobacco Smoke * Based on :Stephens WE; Comparing the cancer potencies of emissions from vapourised nicotine products including e-cigarettes with those of tobacco smoke; Tobacco Control Published Online First: 04 August doi: /tobaccocontrol
18 Understanding Cancer Potency of Carcinogens* Carcinogens Compound IARC Class Tobacco Smoke (n=309) Mean Concentration (μg/ml) Heat-Not-Burn (n=44) E-Cigarettes (n=44) Nicotine Inhaler (n=1) % Reduction* % Reduction* % Reduction* Acrylonitrile 2B % NR 99.8% 1,3 - Butadiene % NR 99.9% Acetaldehyde 2B % 99.8% NR BDL: Below detection limit; NR: Not reported * compared to Tobacco Smoke * Based on :Stephens WE; Comparing the cancer potencies of emissions from vapourised nicotine products including e-cigarettes with those of tobacco smoke; Tobacco Control Published Online First: 04 August doi: /tobaccocontrol
19 Understanding Cancer Potency of Carcinogens* Carcinogens Compound IARC Class Tobacco Smoke (n=309) Mean Concentration (μg/ml) Heat-Not-Burn (n=44) E-Cigarettes (n=44) Nicotine Inhaler (n=1) % Reduction* % Reduction* % Reduction* Acrylonitrile 2B % NR 99.8% 1,3 - Butadiene % NR 99.9% Acetaldehyde 2B % 99.8% NR Formaldehyde % 94.7% NR Cadmium BDL 94.9% 99.5% BDL: Below detection limit; NR: Not reported * compared to Tobacco Smoke * Based on :Stephens WE; Comparing the cancer potencies of emissions from vapourised nicotine products including e-cigarettes with those of tobacco smoke; Tobacco Control Published Online First: 04 August doi: /tobaccocontrol
20 Understanding Cancer Potency of Carcinogens* Carcinogens Compound IARC Class Tobacco Smoke (n=309) Mean Concentration (μg/ml) Heat-Not-Burn (n=44) E-Cigarettes (n=44) Nicotine Inhaler (n=1) % Reduction* % Reduction* % Reduction* Acrylonitrile 2B % NR 99.8% 1,3 - Butadiene % NR 99.9% Acetaldehyde 2B % 99.8% NR Formaldehyde % 94.8% NR Cadmium BDL 94.9% 99.5% TSNA - NNN % 99.96% BDL TSNA - NNK % 99.7% BDL Mean Life Time Cancer Risk* BDL: Below detection limit; NR: Not reported * compared to Tobacco Smoke * Based on :Stephens WE; Comparing the cancer potencies of emissions from vapourised nicotine products including e-cigarettes with those of tobacco smoke; Tobacco Control Published Online First: 04 August doi: /tobaccocontrol
21 Cancer Potency of Carcinogens of Nicotine and Tobacco Containing Products Based on: Stephens WE; Comparing the cancer potencies of emissions from vapourised nicotine products including e-cigarettes with those of tobacco smoke; Tobacco Control Published Online First: 04 August doi: /tobaccocontrol
22 % of Reference Cigarette Example: FDA Study on IQOS Emissions 100% 0 Cigarette 80% 20 60% 40 >90% >90% >80% >92% >98% 40% 60 20% 80 0% 100 Acrolein B[a]P Formaldehyde NNN NNK Note: Intense Health Canada s Smoking Regime; Comparison on a per-stick basis; Excludes Nicotine, Glycerin and Total Particulate Matter Source: FDA Briefing Book for TPSAC, Page 12 as accessed at 22
23 How Cigarette Smoke Causes Cancer? Genetic damage the match that lights the fire * Toxic Cigarette Emissions Inflammation fuel that feeds the flames * Carcinogens Solid Ultrafine Particles** HPHCs Tumor initiation Cancer Tumor progression & Invasiveness*** * Balkwill F and Mantovani A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357: ** You et al. Nanoparticulate carbon black in cigarette smoke induces DNA cleavage and Th17-mediated emphysema. elife 2015; 4:e09623 *** Rothwell et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377:
24 How Smoking Cessation Decreases Cancer Risk Genetic damage the match that lights the fire * Inflammation fuel that feeds the flames * Carcinogens Smoking Cessation 1. Reduces Genetic damage 2. Reduces Inflammation Reduces the risk of lung cancer Solid Ultrafine Particles** HPHCs Tumor initiation Cancer Tumor progression & Invasiveness*** * Balkwill F and Mantovani A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357: ** You et al. Nanoparticulate carbon black in cigarette smoke induces DNA cleavage and Th17-mediated emphysema. elife 2015; 4:e09623 *** Rothwell et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377:
25 How Much Can ENDS Reduce Cancer Risk? Genetic damage the match that lights the fire *? ENDS +? Inflammation fuel that feeds the flames * Carcinogens Questions By how much can alternative products:? 1. Reduce Genetic damage? 2. Reduce Inflammation? 3. Reduce the risk of lung cancer? Solid Ultrafine Particles** HPHCs Tumor initiation Cancer Tumor progression & Invasiveness*** * Balkwill F and Mantovani A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357: ** You et al. Nanoparticulate carbon black in cigarette smoke induces DNA cleavage and Th17-mediated emphysema. elife 2015; 4:e09623 *** Rothwell et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: Electronic Nicotine Delivery Systems. 25
26 Smoking Prevalence Globally and in Korea Why less harmful alternatives are needed 26
27 People will continue to smoke Worldwide it is estimated that more than 1 billion people will continue to smoke in the foreseeable future. 1 According to the ACS more than 46,700 death are attributable to smoking-related diseases every year in Korea. 2 More than 18% of the population (~33% of males) continue to smoke cigarettes in Korea American Cancer Society: 3 OECD Health Statistic 2018, as accessed on August 28 th
28 Emerging Smoke-Free Regulatory Trends new product innovations could make a lot of sense and help people transfer off cigarettes - Scott Gottlieb, Commissioner Food & Drug Administration help people to quit smoking by permitting innovative technologies that minimise the risk of harm / maximise the availability of safer alternatives to smoking heat-not-burn, snus, moist snuff, dissolvable and inhaled nicotine may be significantly safer than cigarettes. - Nicky Wagner, Former Associate Health Minister Growing number of countries are recognizing the benefit of novel smoke-free products 28
29 Scientific Update PMI s Evidence on IQOS related to Cancer Prof. Manuel C. Peitsch PMI Chief Scientific Officer
30 Agenda Totality of Evidence on IQOS to date Can switching to IQOS reduce genetic damage, inflammation? Can switching to IQOS reduce the risk of lung cancer? 30
31 Totality of Evidence on IQOS Toxic Cigarette Emissions Exposure Molecular changes Disruption of biological Mechanisms Cell/Tissue Changes Disease Population Harm Reduced Emissions Reduced Exposure Reduced Adverse Health Effects PMI 18 Non-Clinical Studies and 10 Clinical Studies 31
32 Reduced Formation: by Disease Category Toxic Cigarette Emissions Exposure Molecular changes Disruption of biological Mechanisms Cell/Tissue Changes Disease Population Harm Reduced Emissions Reduced Exposure Reduced Adverse Health Effects PMI Reduced Emissions of Exposure Reduction Harmful Chemicals in IQOS users Carcinomas in 18 Non-Clinical Studies and 10 Clinical Studies No solid ultrafine particles (PM 2.5) Effect on By- Standers Incidence of Lung animal model significantly reduced 32
33 How Cigarette Smoke Causes Cancer? Genetic damage the match that lights the fire * Inflammation fuel that feeds the flames * Carcinogens Questions Does switching from cigarettes to IQOS 1. Reduce Genetic damage? 2. Reduce Inflammation? 3. Reduce the risk of lung cancer? Solid Ultrafine Particles** HPHCs Tumor initiation Cancer Tumor progression & Invasiveness*** * Balkwill F and Mantovani A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357: ** You et al. Nanoparticulate carbon black in cigarette smoke induces DNA cleavage and Th17-mediated emphysema. elife 2015; 4:e09623 *** Rothwell et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377:
34 Genetic Damage is Reduced by IQOS Does Switching to IQOS Reduce Genetic damage? Genetic damage the match that lights the fire * Evidence from IQOS Assessment Reduced Emission of Carcinogens Carcinogens Reduced Exposure to Carcinogens Reduced Genotoxicity Reduced DNA Damage Tumor initiation Reduced Exposure Response Reduced Genetic Damage * Balkwill F and Mantovani A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357:
35 % of Reference Cigarette Levels of Harmful Chemicals Significantly Reduced For IQOS Average reductions in emission of harmful or potentially harmful constituents for IQOS compared to levels measured in smoke from the 3R4F reference cigarette by disease category * 100% Reference Cigarette 75% 50% 25% 0% KFDA s analysis of the HNB aerosol also confirmed the on average 90% lower levels of harmful chemicals in the HNB > 95% reduction WHO (9 chemicals) > 90% reduction FDA (18 chemicals) 95% reduction Health Canada (44 chemicals) > 90% reduction PMI (58 chemicals) > 95% reduction aerosol compared to cigarette smoke. Carcinogens (15 chemicals) IQOS Platform 1 * Aerosol collection with Intense Health Canada s Smoking Regime (55 ml puff volume, 2 second puff duration, 30 second interval puff); Comparison on a per-stick basis Reduction calculations exclude Nicotine, Glycerin and Total Particulate Matter The PMI 58 list includes the FDA 18,and the 15 carcinogens of the IARC Groups 1 35
36 P e r c e n t o f C i g a r e t t e E x p o s u r e Reduced Exposure To Carcinogens IQOS Smoking Abstinence Cigarettes 8 0 Acrylonitrile 1, 3-Butadiene o - t o l 1 - O H P 3 - H P M A T o t a l H E M A H M P M A C O H b B [ a ] P 4 - A B P C E M A N N N 2 - N A S - P M A M H B M A 1 - N A N N A L The highest-ranking carcinogens for cigarettes are 1,3-butadiene and acrylonitrile, accounting for more than three-quarters of the cancer potency.. Stephens WE; Comparing the cancer potencies of emissions from vapourised nicotine products including e-cigarettes with those of tobacco smoke; Tobacco Control Published Online First: 04 August doi: /tobaccocontrol
37 Genetic Damage is Reduced by IQOS Note: the switch to IQOS and Switch to cessation study groups were exposed for 2 month to 3R4F cigarette smoke prior to being switched. Cigarette Switch to IQOS Switch to Cessation IQOS Source: Phillips B, Veljkovic E, Boué S, et al. An 8-Month Systems Toxicology Inhalation/Cessation Study in Apoe / Mice to Investigate Cardiovascular and Respiratory Exposure Effects of a Candidate Modified Risk Tobacco Product, THS 2.2, Compared With Conventional Cigarettes. Toxicological Sciences. 2016;149(2): doi: /toxsci/kfv
38 Evidence from IQOS Assessment Inflammation is Reduced by IQOS Reduced Emission of HPHCs and No Solid Ultrafine Particles Does Switching to IQOS Reduce Inflammation? Inflammation fuel that feeds the flames * Reduced Exposure to HPHCs No Exposure to Solid Ultrafine Particles Solid Ultrafine Particles** HPHCs Reduced Lung Inflammation Reduced Inflammation Tumor progression & Invasiveness*** * Balkwill F and Mantovani A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357: ** You et al. Nanoparticulate carbon black in cigarette smoke induces DNA cleavage and Th17-mediated emphysema. elife 2015; 4:e09623 *** Rothwell et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377:
39 Solid Ultrafine Particle Deposition in the Lung Cigarette Smoke Solid Ultrafine Particles 6x10 11 particles ~= 0.7 mg* IQOS Aerosol No Solid Ultrafine Particles Lung Deposition after 6 months Cigarette smoke* IQOS aerosol* * Corresponding nicotine concentrations Apoe-/- mice exposed for 6 months, 3h/day and 5days/week. You et al. Nanoparticulate carbon black in cigarette smoke induces DNA cleavage and Th17-mediated emphysema. elife 2015; 4:e
40 T L y m p h o c y t e C o u n t ( 1 0 5, m e a n S E M ) N e u t r o p h i l C o u n t ( 1 0 5, m e a n S E M ) T o t a l C e l l C o u n t ( 1 0 5, m e a n ± S E M ) M M P a c t i v i t y ( m U / m l, m e a n S E M ) No Lung Inflammation in IQOS Exposed Mice Total Cell Count in BALF MMP Activity in BALF M o n t h 1 * * 3 0 * * M o n t h 5 6 M o n t h 1 M o n t h * * 4 * * p < ( v s S h a m ) * * p < ( v s S h a m ) # # p < ( v s 3 R 4 F ) 1 0 # # p < ( v s 3 R 4 F ) 2 # # # # # # # # # # # # # # # # # # 0 0 A i r 3 R 4 F I Q O S I Q O S I Q O S A i r 3 R 4 F I Q O S I Q O S I Q O S L o w M e d H i g h L o w M e d H i g h T-Lymphocyte Count in BALF Neutrophil Count in BALF 3 M o n t h * * * * M o n t h 5 9 M o n t h 1 M o n t h 5 2 * * 8 * * 7 6 * * p < ( v s S h a m ) 1 # # # # p < ( v s 3 R 4 F ) * * p < ( v s S h a m ) # # p < ( v s 3 R 4 F ) # # # # # # # # # # # # # # # # # # # # # # A i r 3 R 4 F I Q O S I Q O S I Q O S A i r 3 R 4 F I Q O S I Q O S I Q O S L o w M e d H i g h Source: PMI Study Report of Study - Study number L o w M e d H i g h 40
41 How Cigarette Smoke Causes Cancer? Genetic damage the match that lights the fire * Inflammation fuel that feeds the flames * Carcinogens Tumor initiation Questions Does switching from cigarettes to IQOS 1. Reduce Genetic damage? 2. Reduce Inflammation? 3. Reduce the risk of lung cancer? Cancer Solid Ultrafine Particles* HPHCs Tumor progression & Invasiveness*** * Balkwill F and Mantovani A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357: ** You et al. Nanoparticulate carbon black in cigarette smoke induces DNA cleavage and Th17-mediated emphysema. elife 2015; 4:e09623 *** Rothwell et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377:
42 Lung Cancer Study - Design 26.8 µg/l nicotine concentration in IQOS aerosol represents 56 Sticks/day* Study Groups Nicotine in test atmosphere Female A/J mice Male A/J mice Air 0 µg/l n = 75 n = 118 3R4F 13.4 µg/l n = 75 IQOS Low 6.7 µg/l n = 74 IQOS Medium 13.4 µg/l n = 75 IQOS High 26.8 µg/l n = 72 n = 97 month Interim dissections Terminal dissection Terminal dissection n = Number of animals at months 18 assessable for carcinoma incidence µg/l nicotine concentration in IQOS aerosol represents 56 Sticks/day* *FDA, Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Food and Drug Administration, Washington, DC. Stinn et al., 2013, Toxicology. 2013, 305: doi: /j.tox
43 I n c i d e n c e o f L u n g C a r c i n o m a ( %, M e a n S E M ) M u l t i p l i c i t y o f L u n g C a r c i n o m a ( M e a n S E M ) Incidence and Multiplicity of Lung Carcinoma Incidence Bronchiolo-Alveolar Carcinoma Multiplicity Bronchiolo-Alveolar Carcinoma d i f f. S h a m * p < * d i f f. S h a m * p < * d i f f. 3 R 4 F # p < d i f f. 3 R 4 F # p < A i r 3 R 4 F I Q O S I Q O S I Q O S A i r 3 R 4 F I Q O S I Q O S I Q O S L o w M e d H i g h L o w M e d H i g h Incidence and multiplicity of Lung Carcinomas are significantly increased upon exposure to 3R4F smoke compared to air exposure. Source: PMI Study Report of Study - Study number
44 I n c i d e n c e o f L u n g C a r c i n o m a ( %, M e a n S E M ) Incidence and Multiplicity of Lung Carcinoma Incidence Bronchiolo-Alveolar Carcinoma * # d i f f. S h a m * p < d i f f. 3 R 4 F # p < M u l t i p l i c i t y o f L u n g C a r c i n o m a ( M e a n S E M ) Multiplicity Bronchiolo-Alveolar Carcinoma * # d i f f. S h a m * p < d i f f. 3 R # p < # 4 F A i r 3 R 4 F I Q O S I Q O S I Q O S A i r 3 R 4 F I Q O S I Q O S I Q O S L o w M e d H i g h L o w M e d H i g h Incidence and multiplicity of Lung Carcinomas in IQOS exposed mice was significantly lower compared to 3R4F smoke exposed mice and similar to air exposed mice. Source: PMI Study Report of Study - Study number
45 Conclusions IQOS reduces genetic damage compared to continued smoking IQOS reduces inflammation compared to continued smoking IQOS reduces incidence and multiplicity of lung adenomas and lung carcinomas in a validated cancer animal model 45
46 Risk Assessment Model Toxic Cigarette Emissions Exposure Molecular changes Disruption of biological Mechanisms Cell/Tissue Changes Disease Population Harm Reduced Emissions Reduced Exposure Reduced Adverse Health Effects PMI Reduced Emissions of Exposure Reduction Harmful Chemicals in IQOS users Carcinomas in 18 Non-Clinical Studies and 10 Clinical Studies No solid ultrafine particles (PM 2.5) Effect on By- Standers Incidence of Lung animal model significantly reduced 46
47 What We Know Today IQOS is not risk free and is addictive and the best choice is to quit Smokers carry a time-dependent relative risk of disease based on their smoking history when they quit or switch to IQOS IQOS is a much better choice for smokers than to continue smoking cigarettes We all share the responsibility to provide accurate information based on sound science Consumers have the right to receive accurate and non-misleading information to make an informed, better choice for their health 47
48 This Scientific Update is issued for the purpose of publishing and disseminating scientific information and not for advertising or marketing purposes regarding tobacco or nicotine-containing products. The content of this Scientific Update is not and should not be regarded as an offer to sell, or a solicitation of an offer to buy, any product of PMI or its affiliates. The content on this Scientific Update is also not and should not be regarded as a promise, warranty, characterization or guarantee regarding any product of PMI or its affiliates. 48
Smoking and Non-Communicable Diseases in Hong Kong
Smoking and Non-Communicable Diseases in Hong Kong Current Status and the Way Forward Prof. David Khayat Former Head of Medical Oncology at the Pitié-Salpêtrière in Paris Former President of the National
More informationHeat-not-Burn Products: Scientific Assessment of Risk Reduction
Heat-not-Burn Products: Scientific Assessment of Risk Reduction Tobacco Merchants Association 2015 Annual Meeting Moira Gilchrist PhD Philip Morris International R&D May 20th 2015 The Objective is Harm
More informationTobacco Heating System 2.2, A Candidate Modified Risk Tobacco Product: Cardiovascular Disease Risk Assessment
Tobacco Heating System 2.2, A Candidate Modified Risk Tobacco Product: Cardiovascular Disease Risk Assessment Global Forum on Nicotine 2016 Moira Gilchrist PhD Philip Morris International R&D June 17th
More informationThe IQOS Heating System
The IQOS Heating System Tobacco Products Scientific Advisory Committee January 24, 2018 CC-1 Introduction Moira Gilchrist, PhD Vice President Scientific and Public Communications Philip Morris International
More informationHow innovation will deliver a smokefree
How innovation will deliver a smokefree future Innovation and Good Practices in the Health Sector Rui Minhos Head of Regional Scientific Engagement Philip Morris International 6th November 2018 Our contact
More informationModelling the effects of user exposure to harmful emissions across the spectrum of nicotine delivery
Global Nicotine Forum 2018 Modelling the effects of user exposure to harmful emissions across the spectrum of nicotine delivery Ed Stephens University of St Andrews Declaration: No conflicts of interest
More informationAssessment of the Tobacco Heating System (THS) 2.2, A Candidate Modified Risk Tobacco Product: From Concept to Early Clinical Data
Assessment of the Tobacco Heating System (THS) 2.2, A Candidate Modified Risk Tobacco Product: From Concept to Early Clinical Data Global Forum on Nicotine 2015 Bruce D. Clark PhD Philip Morris International
More informationThe IQOS Heating System
The IQOS Heating System Tobacco Products Scientific Advisory Committee January 24, 2018 CC-1 Introduction Moira Gilchrist, PhD Vice President Scientific and Public Communications Philip Morris International
More informationThe importance of offering adult smokers a portfolio of potentially less harmful products
The importance of offering adult smokers a portfolio of potentially less harmful products International Symposium on Nicotine Technology June 15 th 2017 Thomas Mc Grath, PhD PMI R&D, Philip Morris Products
More informationTOBACCO HARM REDUCTION:
TOBACCO HARM REDUCTION: An Overview of PMI s Scientific Approach & Main Results for the Tobacco Heating System (THS) 2.2, a Candidate Modified Risk Tobacco Product Tunis, Tunisia Dr. Nuno Fazenda, on behalf
More informationHeated Tobacco Technology: Science, Behavior and Avoiding Unintended Consequences
Heated Tobacco Technology: Science, Behavior and Avoiding Unintended Consequences Global Forum on Nicotine 2017 Moira Gilchrist PhD Philip Morris International June 16th 2017 Important Information Reduced-Risk
More informationWhat is combustion and why is the absence of combustion important for heat not burn products
What is combustion and why is the absence of combustion important for heat not burn products Global Forum on Nicotine 2017 June 16 th 2017 Thomas Mc Grath PhD PMI R&D, Philip Morris Products S.A., Quai
More informationUK E-Cigarette Summit Relative risks of cancer posed by combustible and vapourising forms of nicotine delivery: Evidence from chemical exposures
UK E-Cigarette Summit 2017 Relative risks of cancer posed by combustible and vapourising forms of nicotine delivery: Evidence from chemical exposures Ed Stephens University of St Andrews Scope of presentation
More informationCARDIOVASCULAR EFFECTS OF THE TOBACCO HEATING SYSTEM (THS) 2.2 COMPARED WITH CONTINUED SMOKING
CARDIOVASCULAR EFFECTS OF THE TOBACCO HEATING SYSTEM (THS) 2.2 COMPARED WITH CONTINUED SMOKING Athens, Greece Dr. Patrick Picavet, M.D., on behalf of: Baker, Gizelle; Haziza, Christelle; Hoeng, Julia;
More informationCARDIOVASCULAR EFFECTS OF THE TOBACCO HEATING SYSTEM (THS) 2.2 COMPARED WITH CONTINUED SMOKING
CARDIOVASCULAR EFFECTS OF THE TOBACCO HEATING SYSTEM (THS) 2.2 COMPARED WITH CONTINUED SMOKING Athens, Greece Dr. Patrick Picavet, M.D., on behalf of: Baker, Gizelle; Haziza, Christelle; Hoeng, Julia;
More informationCardiovascular effects of nicotine vs. cigarette smoke
Cardiovascular effects of nicotine vs. cigarette smoke Dr Konstantinos Farsalinos Researcher Onassis Cardiac Surgery Center, Greece University of Patras, Greece National School of Public Health, Athens-Greece
More informationE-Cigarettes: Current Perspective
E-Cigarettes: Current Perspective Aruni Bhatnagar, Ph.D. Professor of Medicine University of Louisville Louisville, KY Electronic Cigarettes E-cigarettes are electronic nicotine delivery systems (ENDS),
More informationAir Quality assessment during indoor use of the Tobacco Heating System 2.2
Air Quality assessment during indoor use of the Tobacco Heating System 2.2 THS 2.2. is commercialized under the IQOS brand name Maya Mitova, Catherine Goujon Ginglinger, Michel Rotach, Serge Maeder Philip
More informationAir Quality assessment during indoor use of the Tobacco Heating System 2.2
Air Quality assessment during indoor use of the Tobacco Heating System 2.2 THS 2.2. is commercialized under the IQOS brand name Dr Catherine Goujon Ginglinger - Philip Morris International Research & Development,
More informationNon Clinical Toxicology of Nicotine and Aerosol from a Heated Tobacco Product. Patrick Vanscheeuwijck, PhD Director Pre-Clinical Toxicology
Non Clinical Toxicology of Nicotine and Aerosol from a Heated Tobacco Product Patrick Vanscheeuwijck, PhD Director Pre-Clinical Toxicology PMI s Goal for Harm Reduction Offering adult smokers satisfying
More informationThe IQOS Heating System
Script and Slides of Philip Morris International s Presentation before the Tobacco Products Scientific Advisory Committee (TPSAC) 24 January 2018 Slide 1 The IQOS Heating System Tobacco Products Scientific
More informationThe concept that not all tobacco and nicotine products
A Model Risk Continuum for Tobacco and Nicotine Products by Chris Proctor, Sudhanshu Patwardhan, and James Murphy The concept that not all tobacco and nicotine products present the same risks to human
More informationLung Cancer Epidemiology & Prevention. A/Prof Fraser Brims
Lung Cancer Epidemiology & Prevention A/Prof Fraser Brims Introduction Lung cancer burden Global, Australia, WA Current smoking rates Other risks and associations Prevention Tobacco control E-cigarettes
More informationELECTRONIC CIGARETTES WHAT S THE BOTTOM LINE?
ELECTRONIC CIGARETTES WHAT S THE BOTTOM LINE? E-cigarettes have the potential to benefit adult smokers who are not pregnant if used as a complete substitute for regular cigarettes and other smoked tobacco
More informationNew & Emerging Tobacco Products. Linda Bauld & Kamran Siddiqi
New & Emerging Tobacco Products Linda Bauld & Kamran Siddiqi Outline Electronic cigarettes Heat not burn tobacco Smokeless tobacco Waterpipes Terminology E-cigarettes are not a single product Debate about
More informationRE: Docket No. FDA-2014-N , Electronic Cigarettes and the Public Health
VIA ELECTRONIC SUBMISSION June 30, 2015 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 RE: Docket No. FDA-2014-N-1936-0001, Electronic
More informationPhilip Morris International R&D, Philip Morris Products S.A., Switzerland. 2
Comparative assessment of lung inflammation, pulmonary function and emphysema caused by the aerosol from potential Reduced Risk Products and cigarette smoke in mouse models of COPD. 11 July, 216 COPD-216
More information00:08 For decades our scientists have endeavoured to reduce the risks of tobacco use and continue to do so today. 00:15
00:00 British American Tobacco 00:02 00:03 The Electronic Cigarette 00:07 00:08 For decades our scientists have endeavoured to reduce the risks of tobacco use and continue to do so today. 00:15 00:15 Our
More informationFDLI Annual Conference
FDLI Annual Conference Panel Tobacco Harm Reduction: Opportunities & Regulatory Pathways to Achieve May 5, 2017 Joe Murillo Vice President, Regulatory Affairs Altria Client Services Panel Discussion at
More informationMight Smoking Rates go up in Flames? Dr John Schoonbee, Chief Medical Officer, Swiss Re
Might Smoking Rates go up in Flames? Dr John Schoonbee, Chief Medical Officer, Swiss Re 2 Agenda Smoking is still a problem Stopping is hard Electronic cigarettes Reduced Risk tobacco products Males >15yr
More informationAN UPDATE ON FDA S COMPREHENSIVE PLAN ON TOBACCO AND NICOTINE
AN UPDATE ON FDA S COMPREHENSIVE PLAN ON TOBACCO AND NICOTINE Mitch Zeller, J.D. Director, FDA May 3, 2018 CENTER FOR TOBACCO PRODUCTS HOW CAN WE MAKE THE GREATEST IMPACT? We truly find ourselves at a
More informationA study to examine changes in exposure to cigarette smoke chemicals when a smoker switches to using a tobacco heating product. Part I: Study Design.
A study to examine changes in exposure to cigarette smoke chemicals when a smoker switches to using a tobacco heating product. Part I: Study Design. Nathan Gale 1, Mike McEwan 1, Alison Eldridge 1, Neil
More informationTobacco-related risk perceptions in the regulation of tobacco products at the FDA Center for Tobacco Products
Tobacco-related risk perceptions in the regulation of tobacco products at the FDA Center for Tobacco Products David B. Portnoy, PhD, MPH Conrad J. Choiniere, PhD Office of Science FDA, Center for Tobacco
More informationChanges in Biological and Functional Markers after Six Months, in Three Populations: THS 2.2 (IQOS ) Users, Continued Smokers, and Smoking Abstinence
Changes in Biological and Functional Markers after Six Months, in Three Populations: THS 2.2 (IQOS ) Users, Continued Smokers, and Smoking Abstinence Christelle Haziza, PhD Manager Clinical Science Philip
More informationEvaluation of the Potential for Second-hand Exposure to E-cigarette Aerosol in an Office Environment
Evaluation of the Potential for Second-hand Exposure to E-cigarette Aerosol in an Office Environment Edward A. Robinson, Robert D. Leverette, and Manoj Misra Lorillard Tobacco Company 68 th TSRC Charlottesville,
More informationE-Cigarette Update: Secondhand Vapour
E-Cigarette Update: Secondhand Vapour Toxicity and Health Effects The popularity of e-cigarettes continues to increase, with more Canadians than ever using them indoors and out. The scientific evidence
More informationModified Risk Tobacco Product Applications A Succinct ENDS Industry Perspective
Modified Risk Tobacco Product Applications A Succinct ENDS Industry Perspective Patricia I. Kovacevic General Counsel, Chief Compliance Officer Presentation to the Food and Drug Law Institute Tobacco Conference,
More informationFDA S CENTER FOR TOBACCO PRODUCTS: AN UPDATE ON REGULATORY ACTIVITIES AND PRIORITIES
FDA S CENTER FOR TOBACCO PRODUCTS: AN UPDATE ON REGULATORY ACTIVITIES AND PRIORITIES Mitch Zeller, J.D. (Director, FDA CTP) Matthew R. Holman, Ph.D. (Director, Office of Science, FDA CTP) Kathy Crosby
More informationUPDATE ON PREMARKET TOBACCO PRODUCT AUTHORIZATION PATHWAY
UPDATE ON PREMARKET TOBACCO PRODUCT AUTHORIZATION PATHWAY Presented by Ii-Lun Chen, M.D Director Division of Individual Health Science Office of Science, CTP, FDA Disclaimer: This is not a formal dissemination
More informationElectronic Cigarettes: What we know so far
Electronic Cigarettes: What we know so far Dr. Lynne Dawkins Drugs and Addictive Behaviours Research Group (DABRG), School of Psychology http://www.uel.ac.uk/psychology/research/drugs What I m going to
More informationBiomarker of Exposure Reductions Upon Switching for 5 Days from Cigarettes to a Carbon Heated Tobacco Product (CHTP 1.0)
Biomarker of Exposure Reductions Upon Switching for Days from to a Carbon Heated Tobacco Product () A. Donelli, C. Tran, C. Haziza, J. Ancerewicz, G. de La Bourdonnaye, R. Weitkunat, and F. Lüdicke 8 healthy
More informationTobacco Control Research and Education, University of California San Francisco, San Francisco, CA, USA
The Difference between IQOS and Continued Smoking Response to the article entitled PMI s own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different
More informationFDA Center for Tobacco Products: Tobacco Research and the Population Assessment of Tobacco and Health (PATH) Study
FDA Center for Tobacco Products: Tobacco Research and the Population Assessment of Tobacco and Health (PATH) Study Regulatory Public Laws Compliance & Education Policies Science & Enforcement & Communications
More informationShould FDA try to move smokers to e-cigarettes or other less harmful tobacco-nicotine products and, if so, how?
Should FDA try to move smokers to e-cigarettes or other less harmful tobacco-nicotine products and, if so, how? Jeff Weiss General Counsel/EVP of Gov. Affairs of NJOY, LLC FDLI - October 20, 2017 FDA s
More informationElectronic Cigarettes, Nicotine and Policy Implications
Electronic Cigarettes, Nicotine and Policy Implications Neal L Benowitz MD University of California San Francisco The E-Cigarette Summit The Royal Society London November 17, 2016 Disclosures Dr Benowitz
More informationIntroduction. Principles
NHS Health Scotland s position statement on Electronic Nicotine Delivery Systems ENDS - e-cigarettes and other smoking simulator products 31 October 2014 Introduction NHS Health Scotland is the national
More informationPeter G. Shields, MD Tobacco Products Scientific Advisory Committee (TPSAC) August 16, 2013
Peter G. Shields, MD Tobacco Products Scientific Advisory Committee (TPSAC) August 16, 2013 Conceptual Framework for Evaluating MRTPs: Objectives Provide a framework for evaluating all tobacco products
More informationToxic Contents and Emissions in Smokeless Tobacco Products
Article 9 and 10 Toxic Contents and Emissions in Smokeless Tobacco Products www.untobaccocontrol.org/kh/smokeless-tobacco/ Article 9 and 10 Contents What is Article 9 & 10. Current Status Regarding Implementation
More informationHarmful and potentially harmful constituents in e-cigarettes
Harmful and potentially harmful constituents in e-cigarettes Prof. Riccardo Polosa Institute of Internal Medicine Centre for the Prevention and Cure of Tabagism University of Catania - ITALY Global Forum
More informationHarmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke;
This document is scheduled to be published in the Federal Register on 04/03/2012 and available online at http://federalregister.gov/a/2012-07727, and on FDsys.gov 4160-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationThe Burden of Tobacco, Tobacco Control, and Advocacy: Policy Strategies for Oral Health. Robert McMillen, PhD
The Burden of Tobacco, Tobacco Control, and Advocacy: Policy Strategies for Oral Health Robert McMillen, PhD Tobacco Products Smokeless Tobacco and Health Cancer Oral Disease Reproductive and Developmental
More informationThe Latest on Vaping Among U.S. Teens
The Latest on Vaping Among U.S. Teens Jon Macy, PhD, MPH Indiana University School of Public Health Bloomington Presentation Outline Overview of Electronic Nicotine Delivery Systems (ENDS) New Prevalence
More informationSmoking, e-cigs and reduced risk products. Dr John Schoonbee, IMS November 2017
Smoking, e-cigs and reduced risk products Dr John Schoonbee, IMS November 2017 2 The storyline smoking is bad yet many folks still smoke because quitting is very hard is it better, if one cannot quit,
More informationTHE INFLUENCE OF CIGARETTE FILTER DESIGN ON THE YIELD AND COMPOSITION OF CIGARETTE SMOKE
THE INFLUENCE OF CIGARETTE FILTER DESIGN ON THE YIELD AND COMPOSITION OF CIGARETTE SMOKE Dr M J Taylor Director of Scientific Development Essentra Scientific Services CORESTA Congress Quebec 12 to 16 October
More informationResource 7 (Activity 2) Smoking Quiz
Resource 7 (Activity 2) Smoking Quiz True False 1. 3,000 people in Northern Ireland die as a result of smoking each year. 2. 84% of all lung cancer deaths are caused by smoking. 3. It is legal to smoke
More informationE-Cigarettes and Vapes
E-Cigarettes and Vapes What You Need to Know Education for Parents/Guardians Electronic Nicotine Delivery Device $3 Billion Global Industry 600 + Brands 8000+ Flavors & Liquids Less than a decade ago,
More informationNext Generation Products Sandra Costigan, Marianna Gaca, ChuanLiu, Kevin McAdam, James J. Murphyand Christopher Proctor British American Tobacco 21
Next Generation Products Sandra Costigan, Marianna Gaca, ChuanLiu, Kevin McAdam, James J. Murphyand Christopher Proctor British American Tobacco 21 st October 2015 Contents Evolution of products across
More informationPreventing Youth Electronic Cigarette Use: Partnering with Schools
Preventing Youth Electronic Cigarette Use: Partnering with Schools Kris Minard Montana Office of Public Instruction Tobacco Use Prevention Education Kminard@mt.gov (406) 444-0785 I work for the State of
More informationBecause PMI application did not report the full range of HPHCs in IQOS aerosol,
Because PMI application did not report the full range of HPHCs in IQOS aerosol, characterize HPHCs in sidestream emissions, include a non-targeted analysis of chemicals in emissions, or conduct clinical
More informationInvestor Day Reduced-Risk Products Lausanne, September 29, 2016
Investor Day Reduced-Risk Products Lausanne, September 29, 2016 Manuel Peitsch Chief Scientific Officer, Reduced-Risk Products Mirek Zielinski President, Reduced-Risk Products Investor Day Reduced-Risk
More informationThe Effect of Puff Profile and Volume on the Yields of E-Cigarettes
The Effect of Puff Profile and Volume on the Yields of E-Cigarettes Dr M J Taylor, Filtrona Technology Centre Smoke Science/Product Technology Meeting Seville, Spain, 29 September to 03 October 2013 Introduction
More informationNational Conference of State Legislatures Legislative Summit: Clearing the Air About E-Cigarettes
National Conference of State Legislatures Legislative Summit: Clearing the Air About E-Cigarettes Jack Henningfield Ph.D. Vice President, Research and Health Policy Pinney Associates And Professor, Adjunct,
More informationDissolvable Tobacco Products: Chemistry & Toxicology
Dissolvable Tobacco Products: Chemistry & Toxicology Tobacco Products Scientific Advisory Committee July 21-22, 2011 Charles D. Garner, Ph.D., DABT, CIH Sr. Director, Regulatory Oversight Presentation
More informationExperimental trial on the effectiveness of IQOS compared to e-cigarettes and regular tobacco cigarettes
Global Forum on Nicotine Rethinking Nicotine 2018 Experimental trial on the effectiveness of IQOS compared to e-cigarettes and regular tobacco cigarettes Effects on acute craving, withdrawal, positive
More informationSPIT TOBACCO & SPITLESS TOBACCO
SPIT TOBACCO & SPITLESS TOBACCO Spit tobacco (often called smokeless by the tobacco industry) is being marketed as a safe alternative to smoking, but SMOKELESS IS NOT HARMLESS! Spit Tobacco Chewing tobacco
More informationReduced-Risk Products Science Update
Reduced-Risk Products Science Update Dr. Ian Jones, PhD JTI VP, Reduced-Risk Products Science Forward-Looking Statements This presentation contains forward-looking statements. These statements appear in
More informationFORMs of TOBACCO. 2 nd of 3 Prep for Session 1
FORMs of TOBACCO 2 nd of 3 Prep for Session 1 FORMS of TOBACCO Cigarettes Spit tobacco (chewing tobacco, oral snuff) All forms of tobacco are harmful. Pipes Cigars Clove cigarettes Bidis Hookah (waterpipe)
More informationPROCEDURE FOR GENERATION AND TESTING OF MAINSTREAM TOBACCO HEATING SYSTEM (THS or IQOS) AEROSOL USING A LINEAR SMOKING MACHINE
PROCEDURE FOR GENERATION AND TESTING OF MAINSTREAM TOBACCO HEATING SYSTEM (THS or IQOS) AEROSOL USING A LINEAR SMOKING MACHINE 1 P age Table of contents / Table des matières 1 Introduction...3 1 Scope...3
More informationPrevent disease Protect from injury Promote healthy lifestyles
https://youtu.be/9dzs_rniak0 Prevent disease Protect from injury Promote healthy lifestyles Objectives 1. Obtain a better understanding of local policies that make a difference 2. Establish a plan of action
More informationLow-Nitrosamine Dissolvable Tobacco Products Star Scientific, Inc. Part III Initiation and Cessation
Low-Nitrosamine Dissolvable Tobacco Products Star Scientific, Inc. Part III Initiation and Cessation Using science to reduce tobacco-related harm at every level of the population 1 Summary - Parts I &
More informationBiomarkers in Public Health: Development and Applications
Biomarkers in Public Health: Development and Applications Irina Stepanov, Ph.D. Assistant Professor Division of Environmental Health Sciences and Masonic Cancer Center University of Minnesota Biomarker
More informationDetailed analysis of the Executive Summary (Section 2.7) submitted by Philip Morris International in support of its MRTP application for IQOS
Detailed analysis of the Executive Summary (Section 2.7) submitted by Philip Morris International in support of its MRTP application for IQOS Stanton A. Glantz, Ph.D. and Lauren K. Lempert, JD, MPH UCSF
More informationRISK FROM E-VAPOUR PRODUCTS FOR USERS AND BYSTANDERS
RISK FROM E-VAPOUR PRODUCTS FOR USERS AND BYSTANDERS Dr Konstantinos Farsalinos Researcher Onassis Cardiac Surgery Center, Greece University of Patras, Greece COI Past 36 months 1 study funded by non-profit
More informationREGULATORY OPTIONS FOR MOVING TO THE ELIMINATION OF SMOKING. Ron Borland PhD
REGULATORY OPTIONS FOR MOVING TO THE ELIMINATION OF SMOKING Ron Borland PhD Tobacco Smoking Extremely harmful to health Kills over half of long-term users Reduces quality life years in most Slows recovery
More informationMODIFIED RISK TOBACCO PRODUCT MARKETING DECISIONS
MODIFIED RISK TOBACCO PRODUCT MARKETING DECISIONS Presented by David Ashley, Ph.D. Rear Admiral (retired), US Public Health Service Director, Office of Science, CTP, FDA Disclaimer: This is not a formal
More informationGlobal impact of FDA-inspired tobacco regulatory science on jobs for chemists
Global impact of FDA-inspired tobacco regulatory science on jobs for chemists Sarah Cooney and Chris Proctor Group Research & Development, British American Tobacco, UK American Chemical Society Fall Meeting,
More informationΕΝΑΛΛΑΚΤΙΚΕΣ ΜΟΡΦΕΣ ΚΑΠΝΙΣΜΑΤΟΣ
ΕΝΑΛΛΑΚΤΙΚΕΣ ΜΟΡΦΕΣ ΚΑΠΝΙΣΜΑΤΟΣ E CIGARETTE ENDS:ELECTRONIC NICOTINE DELIVERY S Y S TEM) ΗΕΑΤ-ΝΟΤ-ΒURN CIGARETTES (IQOS) Κουρέα Καλλιρρόη Καρδιολόγος NICOTINE DELIVERY SYSTEMS NICOTINE DELIVERY SYSTEMS
More informationJuly 10, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
July 10, 2017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Comments on Food and Drug Administration Docket No. FDA-2016-N-2527,
More informationDavid S. Goya, DO, MBA, FCCP, FACP Kaiser Permanente Medical center Santa Clara, California
* * David S. Goya, DO, MBA, FCCP, FACP Kaiser Permanente Medical center Santa Clara, California None Electric Cigarette was patented in 1965 by Herbert Gilbert First introduced into the marketplace in
More informationEffects of Product Format on Nicotine and TSNA Extraction from Snus Pouches
Effects of Product Format on Nicotine and TSNA Extraction from Snus Pouches Nathan Gale, Graham Errington and Kevin McAdam Group Research & Development, British American Tobacco, Southampton, UK 67th Tobacco
More informationRationale for Establishing Tobacco Product Regulation
Rationale for Establishing Tobacco Product Regulation Erik Dybing, MD, PhD Conference of the Parties Technical Briefing Geneva, 7 February 2006 WHO Strategy for Tobacco Control Preventing uptake of tobacco
More informationPresenter Disclosures
If the 20th Century was the Cigarette Century, What Will the 21st Century Be? Gary Giovino School of Public Health and Health Professions University at Buffalo ggiovino@buffalo.edu New York State Cessation
More informationIf the 20th Century was the Cigarette Century, What Will the 21st Century Be?
If the 20th Century was the Cigarette Century, What Will the 21st Century Be? Gary Giovino School of Public Health and Health Professions University at Buffalo ggiovino@buffalo.edu New York State Cessation
More informationKevin Walton, Ph.D. Chief, Clinical Research Grants Branch Division of Therapeutics and Medical Consequences NIDA. No disclosures
Kevin Walton, Ph.D. Chief, Clinical Research Grants Branch Division of Therapeutics and Medical Consequences NIDA No disclosures NIDA Organizational Chart Office of Diversity & Health Disparities Office
More informationTOBACCO PRODUCT OR MEDICAL PRODUCT?
TOBACCO PRODUCT OR MEDICAL PRODUCT? Priscilla Callahan-Lyon, MD Deputy Director Division of Individual Health Science Office of Science, CTP Grail Sipes, JD Director Office of Regulatory Policy, CDER Disclaimer:
More informationHow to Regulate E-Cigarettes? Are we asking the right questions?
How to Regulate E-Cigarettes? Are we asking the right questions? Eric N. Lindblom Director, Tobacco Control and Food & Drug Law O Neill Institute for National & Global Health Law Georgetown University
More informationExecutive Summary. No Fire, No Smoke: The Global State of Tobacco Harm Reduction 2018
Executive Summary Executive Summary No Fire, No Smoke: The Global State of Tobacco Harm Reduction 2018 3 The GSTHR report maps for the first time the global, regional and national availability and use
More informationWHO work on smokeless tobacco. Dr Vinayak Prasad, WHO HQ Ms Sarah Emami, WHO HQ
WHO work on smokeless tobacco Dr Vinayak Prasad, WHO HQ Ms Sarah Emami, WHO HQ WHO provides technical assistance to Member States on SLT policies and programs: MPOWER package ( key demand reduction measures
More informationThe Economics of Smoking
The Economics of Smoking One of the potential problems (from an economic perspective) with smoking is that there may be an externality in consumption, so there may be difference between the private and
More informationHHS Public Access Author manuscript J Patient Cent Res Rev. Author manuscript; available in PMC 2016 February 04.
In adult smokers unwilling or unable to quit, does changing from tobacco cigarettes to electronic cigarettes decrease the incidence of negative health effects associated with smoking tobacco? A Clin-IQ
More informationThe Effects of Smoking. Best tip: DONT START
The Effects of Smoking Best tip: DONT START Why do people start? Feel older Feel cool Feel different Peer pressure Fit in Fun Media: advertising, TV, movies, music Friends / family Relieve stress / relax
More informationCommunicating the Risk of Nicotine Delivery Products
Communicating the Risk of Nicotine Delivery Products August 10, 2014 ACS National Meeting Jim Solyst June 24, 2014 1 Nicotine Background Key Points The popularity of e-cigarettes has increased the need
More informationAlcohol in Europe and Brief Intervention. Dr Lars Møller Programme Manager World Health Organization Regional Office for Europe
Alcohol in Europe and Brief Intervention Dr Lars Møller Programme Manager World Health Organization Regional Office for Europe Global risk factors ranked by attributable burden of disease 2010 (GBD, Lancet,
More informationDiscussion points on Bill S-5
Disclaimer: The following document was developed to provide a brief set of discussion points for individuals wishing to discuss Bill S-5 with policy makers, politicians, senators or their advisers. It
More informationThe Benefits and Regulations of Electronic Cigarettes
Best Integrated Writing Volume 3 2016 The Benefits and Regulations of Electronic Cigarettes Sarah Kenney Wright State University Follow this and additional works at: http://corescholar.libraries.wright.edu/biw
More informationClassifying Foods as Carcinogenic? A Case Study of Red and Processed Meats.
Classifying Foods as Carcinogenic? A Case Study of Red and Processed Meats. Andrew Milkowski Feb 23, 2016 Outline What is IARC? How are Carcinogen Classifications Determined 2015 IARC Evaluation of Red
More informationCATCH MY BREATH. ASHA Conference: October 12, Marcella Bianco CATCH My Breath Program Manager CATCH Global Foundation
CATCH MY BREATH ASHA Conference: October 12, 2017 Marcella Bianco CATCH My Breath Program Manager CATCH Global Foundation marcella@catch.org Valerie Phillips Athletic Coordinator/Head of PE Department
More informationElectronic Nicotine and Non Nicotine Delivery Systems (ENDS)
Electronic Nicotine and Non Nicotine Delivery Systems (ENDS) Dr Meena Dawar Medical Health Officer 30 September 2014 1 VCH MHO Recommendations 1. Include e-cigarettes and related ENDS devices in the City
More informationResponsible Practice in E-Vapour Products (EVP) Product Stewardship
Responsible Practice in E-Vapour Products (EVP) Product Stewardship Tanvir Walele, MSc, ERT 11 October 2016 1 Responsible Practice Responsible practice can be divided in to 3 areas: Pre-market product
More information